Skip to main navigation Skip to search Skip to main content

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Project: Research project

Grant Details

StatusActive
Effective start/end date12/14/2311/30/28

Funding

  • HHS: National Institutes of Health (NIH): $3,950,448.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.